Skip to main content
AVBP
NASDAQ Life Sciences

ArriVent Posts $40.3M Q3 Loss, $393.2M Cash to Mid-2028; R&D Chief Lutzker to Retire

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$14.16
Mkt Cap
$698.197M
52W Low
$11.36
52W High
$35.83
52W Position info
25% above low
Off High info
60% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

AVBP sits 25% above its 52-week low of $11.36.

Summary

ArriVent reported a $40.3M Q3 net loss and $393.2M in cash it says funds operations to mid-2028, while announcing R&D chief and co-founder Stuart Lutzker will retire December 1 with CMO Priti Patel taking over R&D.


Key Events · Earnings and Guidance · AVBP

  • Q3 Loss Widens, Runway Extended

    Net loss was $40.3M ($0.81 per share) for Q3 2026 versus $34.98M a year ago; nine-month net loss was $133.5M versus $130.8M.

  • Cash Funds Operations to Mid-2028

    Cash and investments totaled $393.2M at September 30, 2026, which the company expects to fund operations to mid-2028.

  • R&D Chief Lutzker to Retire

    Co-founder and President of R&D Stuart Lutzker retires effective December 1, 2026, receiving a one-time $428,438.21 payment; no disagreement with the company was cited.

  • CMO Patel Takes Over R&D

    Chief Medical Officer Priti Patel assumes leadership of the R&D function effective December 1, 2026.


Analysis · AVBP · Life Sciences

The quarter itself is unremarkable — the net loss widened to $40.3M from $35.0M a year ago and R&D spend was roughly flat. What matters is the runway: $393.2M in cash and investments is now guided to fund operations to mid-2028, roughly 18 months out from today, which buys time to sort out firmonertinib after the October FURVENT failure. The leadership change is the second piece: co-founder and R&D head Stuart Lutzker, who built the ADC pipeline, retires December 1 and CMO Priti Patel takes over R&D — a $428,438.21 one-time payment covers the transition. Investors get a firmonertinib update in Q1 2027 and ARR-217 Phase 1b data in H1 2027.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AVBP was trading at $14.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $698.2M. The 52-week trading range was $11.36 to $35.83. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AVBP - Latest Insights

AVBP
Nov 09, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $14.16 info
Change: $0 (0%) info
Market Cap: $698.197M info
AVBP
Nov 09, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $14.16 info
Change: $0 (0%) info
Market Cap: $698.197M info
AVBP
Oct 26, 2026, 6:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.30
Real-time Price: $14.16 info
Change: -$9.14 (-39%) info
Market Cap: $698.197M info
AVBP
Oct 12, 2026, 5:29 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $16.46
Real-time Price: $14.16 info
Change: -$2.30 (-14%) info
Market Cap: $698.197M info
AVBP
Oct 06, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $28.70
Real-time Price: $14.16 info
Change: -$14.54 (-51%) info
Market Cap: $698.197M info